SailPoint Named a Leader in the 2018 Gartner Magic Quadrant for Identity Governance and Administration for the Fifth Consecutive Time
SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance , today announced it has once again been named a Leader in Gartner’s “Magic Quadrant for Identity Governance and Administration (IGA),” published on February 21, 2018. After Gartner conducted a company and product evaluation of SailPoint’s IGA solutions, SailPoint was named a Leader based on its completeness of vision and ability to execute.
SailPoint is focused on staying at the forefront of innovation in identity governance, developing identity solutions that keep pace with the increasing global regulatory landscape and heightened risk of cyber threats targeting identities while helping IT departments be more efficient in enabling users. SailPoint continues to push the boundaries of the IGA market definition, driving innovation around identity analytics and extending its platform to govern access to data stored in files.
SailPoint currently has 930+ customers, who represent the world’s largest companies in virtually every industry including, 6 of the top 15 banks, 4 of the top 6 healthcare insurance and managed care providers, and 11 of the 15 largest federal agencies. As evidence of the company’s ability to continue innovating its identity platform, SailPoint consistently maintains a 95+ percent customer retention rate.
“SailPoint is redefining IGA. It is no longer sufficient to govern access to structured data, it is now necessary to also govern access to data stored in files,” said Kevin Cunningham, Chief Strategy Officer and Co-founder for SailPoint. “Identity governance needs to work for all identities, all applications, and all data, while incorporating identity analytics and machine learning to help our customers govern smarter. This is the next frontier in identity governance.”
To read a complimentary copy of the 2018 Gartner Magic Quadrant for Identity Governance and Administration, published on February 21, 2017, please visit: https://www.sailpoint.com/gartner.
SailPoint is a Premier sponsor of the Gartner IAM Summit in London on March 5-6. Visit us in booth P1 and stop by our customer session on Monday, March 5 for a real-world identity governance case study with one of the world’s largest global payments technology companies.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Gartner Identity & Access Management Summit
IAM leaders will learn how to tackle complex issues and generate new ideas to reimagine significant elements of their IAM approach for digital age success. At the Summit, attendees will learn how to safeguard their business from breaches, security incidents or abuse of privilege, but also how to apply the latest techniques to tackle risks in cloud, Internet of Things and IT.
SailPoint: The Power of Identity™
SailPoint, the leader in enterprise identity governance, brings the Power of Identity to customers around the world. SailPoint’s open identity platform gives organizations the power to enter new markets, scale their workforces, embrace new technologies, innovate faster and compete on a global basis. As both an industry pioneer and market leader in identity governance, SailPoint delivers security, operational efficiency and compliance to enterprises with complex IT environments. SailPoint's customers are among the world’s largest companies in a wide range of industries, including: 6 of the top 15 banks, 4 of the top 6 healthcare insurance and managed care providers, 8 of the top 15 property and casualty insurance providers, 5 of the top 15 pharmaceutical companies, and 11 of the largest 15 federal agencies.
SailPoint, the SailPoint logo, IdentityIQ, IdentityNow, IdentityAI, SecurityIQ and all techniques are trademarks or registered trademarks of SailPoint Technologies Holdings, Inc. in the U.S. and/or other countries. All other products or services are trademarks of their respective companies.
SailPoint Technologies Holdings, Inc.
Jessica Sutera, 978-278-5411
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Synteract Announces Collaboration with International Children’s Advisory Network iCAN Research25.6.2018 20:03 | Tiedote
Synteract, an innovative contract research organization (CRO) providing full, phase I-IV services enabling drug development companies to bring new medicines to market, has signed a memo of understanding to partner with the International Children’s Advisory Network (iCAN). A worldwide consortium of children’s advisory groups, iCAN is dedicated to giving children and families a voice in health, medicine, research, and innovation by increasing education about the importance of children’s involvement. Synteract is a sponsor at the 2018 iCAN Research Summit in Edinburgh, Scotland, UK, July 8-13, 2018 and will hold two interactive plenary seminar sessions at the event. With chapters across the U.S. and worldwide, iCAN partners with local children’s hospitals and addresses the needs of pediatric clinical research and healthcare and advocates for patients worldwide. In partnering with iCAN, Synteract will expand its access to children and families familiar with clinical research. iCAN will sup
GA-ASI to Fly First Trans-Atlantic Flight of a MALE RPA25.6.2018 19:55 | Tiedote
On July 10-11, General Atomics Aeronautical Systems, Inc. (GA-ASI) plans to make the first-ever trans-Atlantic flight of a Medium-altitude, Long-endurance (MALE) Remotely Piloted Aircraft (RPA). GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static display July 13-15 for the Royal International Air Tattoo (RIAT) airshow being held at RAF Fairford. The flight and display will commemorate the RAF’s centenary celebration (RAF100). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005946/en/ GA-ASI’s company-owned MQ-9B SkyGuardian RPA is scheduled to fly from the company’s Flight Test and Training Center in Grand Forks, North Dakota, USA, to Royal Air Force (RAF) Fairford in Gloucestershire, UK. The aircraft will then be on static displa
Quadient Announces General Availability of Quadient Inspire R1225.6.2018 17:30 | Tiedote
www.quadient.com : Quadient, the award-winning leader in Customer Communications Management (CCM), announced the general availability of its newest release, Quadient Inspire R12, which includes the new Digital Advantage Suite. The updated version of Quadient Inspire is designed to give customers and partners greater control over the systems and processes used to drive consistent communications across all channels with an emphasis on digital experiences. With Inspire R12, users design omni-channel communications in days rather than months with a simple, modern and comprehensive platform. The solution makes it possible to change designs and test for all channels in minutes, with fully integrated tracking and approval processes built in. Additionally, R12 integrates all parts of the communications process from linking journey maps to communications, postal sorting, address, phone and email verifications, email delivery, SMS delivery, mail delivery tracking, and production monitoring to re
The Dementia Discovery Fund Raises $350 Million25.6.2018 16:00 | Tiedote
The Dementia Discovery Fund (DDF) today announces the completion of its fundraising, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors committed to developing new medicines for dementia. The goal was met today with a new investment of $60 million from US AARP, the global nonpartisan organisation dedicated to empowering Americans 50 and older to choose how they live as they age. The fundraising far exceeded its initial target of $200 million (£130 million), making it the first and largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease. The DDF makes early stage venture capital investments to develop novel disease-modifying therapeutics for all forms of dementia. The fund is managed by SV Health and was formed through the collaboration of leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and
Professor Thierry Philip Takes Office as OECI President25.6.2018 15:22 | Tiedote
Professor Thierry Philip, President of the Institut Curie, has been elected President of the Organisation of European Cancer Institutes ( OECI ) for a three-year term. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005600/en/ Pr Thierry Philip (Photo: Business Wire) At the end of June 2018, Professor Philip, an oncologist and pediatrician, will take over as head of this European organization, which brings together 90 institutes and university centers and whose mission is fully devoted to cancer. This European non-governmental, non-profit organization aims to promote cooperation between its members or associate members and pursues a triple objective: to provide cancer patients in Europe with equal access to high-quality care; to assist European institutes with the implementation of a quality system for oncology care; to promote and accelerate the progress of translational research. In this regard, half of the 90 OECI ce
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes25.6.2018 15:07 | Tiedote
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials in the EASE phase III programme, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in HbA1c after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10, and 25 mg). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005579/en/ Type 1 diabetes currently affects approximately 30 million adults worldwide.1 It is an autoimmune disease in which the body does not produce sufficient amounts of insulin and therefore requires life-long daily insulin administration to regulate blood sugar. For some people with type 1 diabetes, it may be challenging to manage blood sugar levels with insulin alone. People with type
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme